- 1Elevan Biopharmaceuticals will invest $7 million to relocate its headquarters and establish a CDMO site in Fishers, Indiana.
- The company plans to create 120 jobs and begin operations in September 2025.
1Elevan Biopharmaceuticals, Inc. has announced plans to relocate its headquarters from California to Fishers, Indiana, investing $7 million to renovate a 133,500-square-foot facility in the Fishers Life Sciences and Innovation Park. The new site will support peptide therapeutic development, manufacturing, and contract development and manufacturing (CDMO) services.
The company expects to complete renovations by summer 2025, with operations launching in September. The facility will include pharmacy space licensed for category III, 503A/503B compounding and on-site telemedicine providers to manage peptide therapy and prescriptions.
Founded in 2022, 1Elevan Bio selected Indiana for its business environment and growing biotech sector. The relocation will also create 120 new jobs over five years and is supported by satellite sites in California and Florida to enable national service delivery.
“1Elevan Bio chose Fishers, Indiana, because the city is dedicated to supporting biotechnology,” said Darrin Carrico, President and CEO. “It is a rare confluence of biotech companies involved in impactful science, intentionally collaborative, empowering unfettered innovation.”
“Fishers has become a global centre for innovation in the life sciences,” said Fishers Mayor Scott Fadness. “The announcement from 1Elevan is further proof that our strategy to attract forward-thinking companies and skilled talent is working. We’re excited to watch how 1Elevan contributes to the industry in the years ahead.”
